VRNA Financials: Verona Pharma Ltd AI Analysis

Home

Stock

VRNA

Financials

VRNA Financial

Verona Pharma Ltd

$106.91

0.11%

$0.11

At close: Mar 24, 16:00:00 GMT-4

$106.91

Post-market: Mar 24, 19:50:23 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

VRNA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	221	42	0	0	40	0
Revenue Growth (YoY)	--	--	--	-100%	--	--
Cost of Revenue	10	2	0	0	--	--
Gross Profit	210	39	0	0	--	--
Selling, General & Admin	221	149	50	26	33	29
Research & Development	45	44	17	49	79	44
Operating Expenses	266	194	67	75	113	74
Other Non Operating Income (Expenses)	2	3	1	9	15	8
Pretax Income	-72	-163	-53	-68	-55	-65
Income Tax Expense	8	10	0	0	0	0
Net Income	-81	-173	-54	-68	-55	-65
Net Income Growth	-35%	220%	-21%	24%	-15%	63%
Shares Outstanding (Diluted)	727.22	652.31	634.14	529.07	473.19	260.58
Shares Change (YoY)	12%	3%	20%	12%	82%	151%
EPS (Diluted)	-0.12	-0.26	-0.08	-0.13	-0.12	-0.25
EPS Growth	-36%	210%	-34%	8%	-52%	-36%
Free Cash Flow	-73	-122	-50	-59	-33	-45
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	95.02%	92.85%	0%	0%	--	--
Operating Margin	-25.33%	-366.66%	0%	0%	-182.5%	0%
Profit Margin	-36.65%	-411.9%	0%	0%	-137.5%	0%
Free Cash Flow Margin	-33.03%	-290.47%	0%	0%	-82.5%	0%
EBITDA	-55	-153	-67	-75	-73	-74
EBITDA Margin	-24.88%	-364.28%	0%	0%	-182.5%	0%
D&A For EBITDA	1	1	0	0	0	0
EBIT	-56	-154	-67	-75	-73	-74
EBIT Margin	-25.33%	-366.66%	0%	0%	-182.5%	0%
Effective Tax Rate	-11.11%	-6.13%	0%	0%	0%	0%

Follow-Up Questions

What are Verona Pharma Ltd's key financial statements?



According to the latest financial statement (Form-10K), Verona Pharma Ltd has a total asset of $474, Net loss of $-173

What are the key financial ratios for VRNA?



Verona Pharma Ltd's Current ratio is 1.76, has a Net margin is -411.9, sales per share of $0.06.

How is Verona Pharma Ltd's revenue broken down by segment or geography?



Verona Pharma Ltd largest revenue segment is eLMTree, at a revenue of 411,756,000 in the most earnings release.For geography, United States and Rest of World is the primary market for Verona Pharma Ltd, at a revenue of 411,756,000.

Is Verona Pharma Ltd profitable?



no, according to the latest financial statements, Verona Pharma Ltd has a net loss of $-173

Does Verona Pharma Ltd have any liabilities?



yes, Verona Pharma Ltd has liability of 269

How many outstanding shares for Verona Pharma Ltd?



Verona Pharma Ltd has a total outstanding shares of 677

Key Stats

Prev.Close

$106.79

Open

$106.91

Day's Range

$106.91 - $106.91

52 week range

$47.2 - $106.93

Volume

1.8M

Avg.Volume

2.8M

Dividend yield

EPS (TTM)

-0.12

Market Cap

$9.1B

What is VRNA?

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.



Features

AI Copilot for Stock & Crypto

Resources